'Suicide cell' plan to beat breast cancer
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.SCIENTISTS are to try to order cancer cells to 'commit suicide' in the battle to beat breast cancer.
The method centres on a new approach to cancer gene therapy being devised by a team at the Imperial Cancer Research Fund, which has worked out a way of tricking a breast tumour cell into activating a drug that will kill it.
The scientists from the charity's cancer unit at London's Hammersmith Hospital have asked for approval to start trials with 10 volunteer patients with advanced breast cancer. Dr Nick Lemoine, the team leader, said: 'This is the first time anyone has attempted to use a cancer gene to destroy a cancer cell.'
The method, published in the journal Gene Therapy, is called genetic prodrug activation therapy.
Breast cancer has been chosen for the trial because the team identified the molecular 'switch' controlling a gene called erbB-2 which is turned on in breast cancer cells but not in normal cells.
High levels of the protein produced by the gene are found in tumour cells in about a fifth of patients, whose outlook is very poor.
Dr Lemoine said: 'The first trial will not be an attempt to cure. It's fact-finding - checking whether we can make the cells activate the drug in the nodules.
'It works in the laboratory, but that is a long way from making it effective in patients.'
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments